IRODALOM
1. Ajani JA, Mansfield PF, Janjan J, et al.: Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With
Potentially Resectable Gastric Carcinoma. J Clin Oncol 2004 Jul;22:2774-2780.
2. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth
A, Jaeger E.: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced
gastric cancer. J Clin Oncol. 2004 Feb 15;22(4):658-63.
3. Allegrini G, Falcone A, Di Marsico R, Lencioni M, Masi G, Galli C, Cupini S, Pfanner E, Marcucci L, Conte PF.: 5-
fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin:
phase II study in advanced gastric cancer patients. Am J Clin Oncol. 2004 Feb;27(1):101-5.
4. Alpen B, Kuse R, Parwaresch R, Muller-Hermelink HK, Stolte M, Neubauer A.: Ongoing monoclonal B-cell
proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy. J Clin Oncol. 2004 Aug
1;22(15):3039-45.
5. Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y, Yasuda Y, Nagai H, Shirasaka T.: Alternate-day oral therapy
with TS-1 for advanced gastric cancer. Int J Clin Oncol. 2004 Jun;9(3):143-8.
6. Barone C, Cassano A, Pozzo C, D’Ugo D, Schinzari G, Persiani R, Basso M, Brunetti IM, Longo R, Picciocchi A.:
Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Oncology. 2004;67(1):48-53.
7. Berardi R, Scartozzi M, Romagnoli E, Antognoli S, Cascinu S.: Gastric cancer treatment: a systematic review. Oncol
Rep. 2004 Apr;11(4):911-6. Review.
8. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van
Cutsem E, D’haese S, Coens C; European Organisation for Research and Treatment of Cancer Gastrointestinal
and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22,
to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004 Oct;40(15):2260-8.
9. Bora H, Unsal D, Akmansu M.: Results of chemoirradiation after curative resection of locally advanced gastric cancer. Int
J Clin Pract. 2004 May;58(5):451-6.
10. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry
E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C: Federation Francophone de Cancerologie
Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),
LV5FU2 plus cisplatin, or V5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a
Federation Francophone de Cancerologie Digestive Group Study–FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-
28.
11. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, Hochwald SN.: Inducible nuclear factor-kappaB
activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg. 2004 Aug;199(2):249-58.
12. Cao JG, Tang XQ, Shi SH.: Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J
Gastroenterol. 2004 Oct 15;10(20):3062-4.
13. Cascinu S, Scartozzi M, Labianca R, Catalano V, Silva RR, Barni S, Zaniboni A, D’Angelo A, Salvagni S,
Martignoni G, Beretta GD, Graziano F, Berardi R, Franciosi V; Italian Group for the Study of Digestive Tract
Cancer (GISCAD). High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin,
glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group
for the Study of Digestive Tract Cancer (GISCAD). Br. J. Cancer. 2004 Apr 19;90(8):1521-5.
14. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK,
Cheng AL.: Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the
treatment of advanced gastric cancer. Br. J. Cancer. 2004 Aug 2;91(3):453-8.
15. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH.: Survival benefit of metastasectomy for Krukenberg tumors
from gastric cancer. Gynecol Oncol. 2004 Aug;94(2):477-82.
16. Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, Jaeck D, Fagniez PL, Gainant A.: Randomized
trial of adjuvant chemotherapy after curative resection for gastric cancer. Am. J. Surg. 2004 Mar;187(3):440-5.
17. Chun JH, Kim HK, Kim E, Kim IH, Kim JH, Chang HJ, Choi IJ, Lim HS, Kim IJ, Kang HC, Park JH, Bae JM,
Park JG.: Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res.
2004 Jul 15;64(14):4703-6.
18. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM.: Weekly irinotecan in
patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 2004 Jan;34(1):8-13.
19. Chung HT, Shakespeare TP, Wynne CJ, Lu JJ, Mukherjee RK, Back MF.: Evaluation of a radiotherapy protocol
based on INT0116 for completely resected gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004 Aug
1;59(5):1446-53.
20. Ciacci C, Sabbatini F, Cavallaro R, Castiglione F, Di Bella S, Iovino P, Palumbo A, Tortora R, Amoruso D,
Mazzacca G.: Helicobacter pylori impairs iron absorption in infected individuals. Dig Liver Dis. 2004 Jul;36(7):455-60.
21. Correa P, Piazuelo MB, Camargo MC.: The future of gastric cancer prevention. Gastric Cancer. 2004;7(1):9-16.
Review.
22. Correa P.: Is gastric cancer preventable? Gut. 2004 Sep;53(9):1217-9. Review.
23. van Cutsem E.: The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist. 2004;9
Suppl 2:9-15. Review.
24. Detroz B, Laurent S, Honore P, Blaffart F, Limet R, Meurisse.: Rationale for hyperthermic intraperitoneal
chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis. Acta Chir Belg. 2004
Aug;104(4):377-83. Review.
25. Deutsch F, Zilberstein B, Yagi OK, Crescentini F, Deutsch CR, Gama-Rodrigues JJ.: Gastric carcinoma in a 13-yearold
girl. Gastric Cancer. 2004;7(3):178-82.
26. Dickson JL, Cunningham D.: Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol. 2004
Mar;16(3):255-63. Review.
27. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra
M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Parsonnet J, Triadafilopoulos G, Perez-Perez
GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD.: Antimicrobial resistance incidence and risk factors among
Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004 Jun;10(6):1088-94.
28. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, Pera M.: p53 and VEGF expression are
independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br. J. Cancer.
2004 Jan 12;90(1):206-15.
29. Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y.: Anti-cancer effects of COX-2 inhibitors and their correlation with
angiogenesis and invasion in gastric cancer. World J Gastroenterol. 2004 Jul 1;10(13):1971-4.
30. Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J,
Broome P, Michaeli D.: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol. 2004 Jun;30(5):536-43.
31. Glehen O, Mohamed F, Gilly FN.: Peritoneal carcinomatosis from digestive tract cancer: new management by
cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004 Apr;5(4):219-28. Review.
32. Grau JJ, Domingo-Domenech J, Morente V, Pera M, Garcia-Valdecasas JC, Fuster J, Bombi A, Mellado B,
Albanell J, Gascon P.: Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in
resected gastric cancer patients treated with adjuvant tegafur. Oncology. 2004;66(3):226-33.
33. Graziano F, Mandolesi A, Ruzzo A, Bearzi I, Testa E, Arduini F, Silva R, Muretto P, Mari D, Berardi R, Scartozzi
M, Lai V, Cascinu S, Magnani.: Predictive and prognostic role of E-cadherin protein expression in patients with
advanced gastric carcinomas treated with palliative chemotherapy. Tumour Biol. 2004 May-Jun;25(3):106-10.
34. Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, Geisinger KR, Levine EA.: Cytoreductive
surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004 MayJun;8(4):454-63.
35. Hamaguchi K, Ogawa K, Katsube T, Konno S, Aiba M.: Does eradication of Helicobacter pylori reduce the risk of
carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the
residual stomach before and after Helicobacter pylori eradication. Langenbecks Arch. Surg. 2004 Apr;389(2):83-91.
Epub 2004 Feb 06.
36. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der
Bijl J, van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group. Neo-adjuvant chemotherapy
for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004
Aug;30(6):643-9.
37. Hinoda Y, Sasaki S, Ishida T, Imai K.: Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer
Sci. 2004 Aug;95(8):621-5. Review.
38. Hirao K, Hirasaki S, Tsuzuki T, Kajiwara T, Hyodo I.: Unresectable alpha fetoprotein-producing gastric cancer
successfully treated with irinotecan and mitomycin C after S-1 failure. Intern Med. 2004 Feb;43(2):106-10.
39. Hofheinz RD, Willer A, Weisser A, Gnad U, Saussele S, Kreil S, Hartmann JT, Hehlmann R, Hochhaus A.:
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A
phase-I-study in patients with upper gastrointestinal cancer. Br. J. Cancer. 2004 May 17;90(10):1893-7.
40. Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, Watanabe T, Ochiai M, Tanimura H, Tsubota
YT.: Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and
colorectal cancers. Oncol Rep. 2004 May;11(5):1045-51.
41. Hunt R, Fallone C, Veldhuyzan van Zanten S, Sherman P, Smaill F, Flook N, Thomson A; CHSG 2004 participants.
Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori–an
evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J
Gastroenterol. 2004 Sep;18(9):547-54. Review.
42. Hunt RH.: Will eradication of Helicobacter pylori infection influence the risk of gastric cancer? Am J Med. 2004 Sep
6;117 Suppl 5A:86S-91S. Review.
43. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R.:
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br. J.
Cancer. 2004 Oct 4;91(7):1245-50.
44. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T.: Long-term effect of Helicobacter pylori
eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment. Pharm. Ther. 2004 Jun
1;19(11):1181-8.
45. Inoue K, Onishi H, Kato Y, Michiura T, Nakai K, Sato M, Yamamichi K, Machida Y, Nakane Y.: Comparison of
intraperitoneal continuous infusion of floxuridine and bolus administration in a peritoneal gastric cancer xenograft model.
Cancer Chemother Pharmacol. 2004 May;53(5):415-22.
46. Itoh T, Kusaka K, Kawaura K, Kashimura K, Yamakawa J, Takahashi T, Kanda T.: Selective binding of sucralfate
to endoscopic mucosal resection-induced gastric ulcer: evaluation of aluminium adherence. J Int Med Res. 2004 SepOct;32(5):520-9.
47. Kamitsuji Y, Mori S, Kami M, Yamada H, Shirakawa K, Kishi Y, Murashige N, Kim SW, Heike Y, Takaue Y.: Fatal
deep vein thrombosis after allogeneic reduced intensity hematopoietic stem cell transplantation for the treatment of
metastatic gastric cancer. Ann. Hematol. 2004 Aug;83(8):533-5. Epub 2003 Dec 19.
48. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG.: Identification of genes with
differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin
Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84.
49. Kaubisch A, Kaleya R, Haynes H, Rozenblit A, Wadler S.: Phase II clinical trial of parenteral hydroxyurea in
combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and
neuroendocrine tumors. Cancer Chemother Pharmacol. 2004 Apr;53(4):337-40. Epub 2003 Dec 24.
50. Kawashima R, Haisa M, Kimura M, Takaoka M, Shirakawa Y, Takeda H, Uetsuka H, Gunduz M, Nagai N, Tanaka
N, Naomoto Y.: Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU. Int J Oncol.
2004 Feb;24(2):273-8.
51. Kawata K, Kanai M, Sasada T, Iwata S, Yamamoto N, Takabayashi A.: Usefulness of 99mTc-sestamibi scintigraphy
in suggesting the therapeutic effect of chemotherapy against gastric cancer. Clin Cancer Res. 2004 Jun 1;10(11):3788-93.
52. Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH, Shin BA, Ahn BW, Jung YD.: EGCG blocks tumor promoterinduced
MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res.
2004 Mar-Apr;24(2B):747-53.
53. Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE.: 9-Aminocamptothecin (9-AC) given as a
120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A
phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug;22(3):323-7.
54. Kochi M, Fujii M, Kaiga T, Takahashi T, Morishita Y, Kobayashi M, Kasakura Y, Takayama T.: FLEP
chemotherapy for alpha-fetoprotein-producing gastric cancer. Oncology. 2004;66(6):445-9.
55. Koizumi W, Fukuyama Y, Fukuda T, Akiya T, Hasegawa K, Kojima Y, Ohno N, Kurihara M.: Randomized phase II
study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric
cancer. Anticancer Res. 2004 Jul-Aug;24(4):2465-70.
56. Koizumi W, Kurihara M, Hasegawa K, Chonan A, Kubo Y, Maekawa R, Iwasaki R, Sasai T, Fukuyama Y,
Ishikawa K, Miyoshi K, Yasutake K, Hayakawa M.: Sequence-dependence of cisplatin and 5-fluorouracil in advanced
and recurrent gastric cancer. Oncol Rep. 2004 Sep;12(3):557-61.
57. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HP, Dent J, Zeitoun P, Havu
N, Lamm M, Walan A.: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term
omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004
Jan;53(1):12-20.
58. Kwok CM, Wu CW, Lo SS, Shen KH, Hsieh MC, Lui WY.: Survival of gastric cancer with concomitant liver
metastases. Hepatogastroenterology. 2004 Sep-Oct;51(59):1527-30.
59. de Lange SM, van Groeningen CJ, Kroep JR, Van Bochove A, Snijders JF, Peters GJ, Pinedo HM, Giaccone G.:
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann. Oncol. 2004 Mar;15(3):484-8.
60. Layke JC, Lopez PP.: Gastric cancer: diagnosis and treatment options. Am Fam Physician. 2004 Mar 1;69(5):1133-40.
Review.
61. Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, Kim E, Oh SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee
KH, Lee JS, Kim WK, Kim H.: Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol. 2004 Jan;66(1-2):167-
74.
62. Lee SH, Kang WK, Park J, Kim HY, Kim JH, Lee SI, Park JO, Kim K, Jung CW, Park YS, Im YH, Lee MH, Park
K.: Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable
gastric cancer. Br. J. Cancer. 2004 Jul 5;91(1):18-22.
63. Leong T.: Evolving role of chemoradiation in the adjuvant treatment of gastric cancer. Expert Rev Anticancer Ther.
2004 Aug;4(4):585-94. Review.
64. Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ.: Effect of
peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells.
Gut. 2004 Mar;53(3):331-8.
65. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung.: Factors predicting progression of gastric
intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004 Sep;53(9):1244-9.
66. Lindsey H.: Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol. 2004 Sep;5(9):519.
67. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y, Fan D.: Reversal of the malignant phenotype of gastric cancer
cells by inhibition of RhoA expression and activity. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6239-47.
68. Lordick F, Stein HJ, Peschel C, Siewert JR.: Neoadjuvant therapy for oesophagogastric cancer. Br. J. Surg. 2004
May;91(5):540-51. Review.
69. Macdonald JS.: Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol. 2004
Sep;54 Suppl 1:S4-11. Review.
70. Macdonald JS.: Treatment of localized gastric cancer. Semin Oncol. 2004 Aug;31(4):566-73. Review.
71. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S.: Expression of p53 protein as a predictor of the response to 5-
fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin
layer collagen gel. Int J Oncol. 2004 Apr;24(4):807-13.
72. Melichar B, Voboril Z, Cerman J Jr, Melicharova K, Nozicka J, Mergancova J, Voboril R, Jandik P.: Hepatic
arterial infusion chemotherapy in gastric cancer: a report of four cases and analysis of the literature. Tumori. 2004 JulAug;90(4):428-34.
Review.
73. Menges M, Hoehler T.: Innovative drugs and strategies in the treatment of upper gastrointestinal tract carcinomas.
Onkologie. 2004 Feb;27(1):47-53. Review.
74. Mimatsu K, Oida T, Kuboi Y, Kawasaki A, Kanou H, Kaneda H, Amano S.: A long-surviving patient with
unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy. Int J Clin Oncol.
2004 Jun;9(3):193-6.
75. Min YJ, Bang SJ, Shin JW, Kim do H, Park JH, Kim GY, Ko BK, Choi DH, Cho HR.: Combination chemotherapy
with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer. J Korean Med Sci.
2004 Jun;19(3):369-73.
76. Mori T, Fujiwara Y, Sugita Y, Azama T, Ishii T, Taniguchi K, Yamazaki K, Takiguchi S, Yasuda T, Yano M, Monden
M.: Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative
chemotherapy in advanced gastric carcinoma. Ann. Surg. Oncol. 2004 Jan;11(1):14-20.
77. Morita S, Ohashi Y, Hirakawa K, Nakata B, Saji S, Sakamoto J.: Phase I/II study of combination therapy of oral
fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced
gastric cancer: a novel study design to evaluate safety and efficacy. Jpn J Clin Oncol. 2004 Mar;34(3):159-61.
78. Nakajima S, Hattori T.: Oesophageal adenocarcinoma or gastric cancer with or without eradication of Helicobacter
pylori infection in chronic atrophic gastritis patients: a hypothetical opinion from a systematic review. Aliment. Pharm.
Ther. 2004 Jul;20 Suppl 1:54-61. Review.
79. Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, Torigoe T, Sato N, Watanabe N.: Survivin
as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci. 2004 Jan;95(1):44-51.
80. Nakane Y, Inoue K, Michiura T, Nakai K, Sato M, Baden T, Okumura S, Yamamichi K.: Combined S-1 and cisplatin
preoperative chemotherapy for patients with advanced gastric cancer: report of five cases. Hepatogastroenterology. 2004
Jan-Feb;51(55):289-93.
81. Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, Hirakawa K.: Combination phase I trial of a
novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-
9902). Clin Cancer Res. 2004 Mar 1;10(5):1664-9.
82. Nakayama Y, Graham DY.: Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther. 2004
Aug;2(4):599-610. Review.
83. Nardone G, Rocco A, Vaira D, Staibano S, Budillon A, Tatangelo F, Sciulli MG, Perna F, Salvatore G, Di Benedetto
M, De Rosa G, Patrignani P.: Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway
of H pylori-related gastric carcinogenesis. J Pathol. 2004 Mar;202(3):305-12.
84. Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, Yano S, Higami T, Maruyama R.: A randomized consent design
trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer- a single institute study. Anticancer
Res. 2004 May-Jun;24(3b):1879-87.
85. Nishina T, Hyodo I, Miyaike J, Inaba T, Suzuki S, Shiratori Y.: The ratio of thymidine phosphorylase to
dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical
response to 5′-deoxy-5-fluorouridine. Eur J Cancer. 2004 Jul;40(10):1566-71.
86. Panter SJ, O’Flanagan H, Bramble MG, Hungin AP.: Empirical use of antisecretory drug therapy delays diagnosis of
upper gastrointestinal adenocarcinoma but does not effect outcome. Aliment. Pharm. Ther. 2004 May 1;19(9):981-8.
87. Park JK, Lee SH, Kang JH, Nishio K, Saijo N, Kuh HJ.: Synergistic interaction between gefitinib (Iressa, ZD1839)
and paclitaxel against human gastric carcinoma cells. Anticancer Drugs. 2004 Sep;15(8):809-18.
88. Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS, Kim NS.: Identification of novel genes associated with the
response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 2004 Oct 8;214(1):19-33.
89. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK,
Kim HK.: A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric
cancer. Oncol Rep. 2004 Nov;12(5):1059-64.
90. Park YH, Ryoo BY, Choi SJ, Kim HT.: A phase II study of capecitabine and docetaxel combination chemotherapy in
patients with advanced gastric cancer. Br. J. Cancer. 2004 Apr 5;90(7):1329-33.
91. Parsonnet J, Forman D.: Helicobacter pylori infection and gastric cancer- for want of more outcomes. JAMA. 2004 Jan
14;291(2):244-5.
92. Ramnath N, Creaven PJ.: Matrix metalloproteinase inhibitors. Curr Oncol Rep. 2004 Mar;6(2):96-102. Review.
93. Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, Medina-Franco H.: Clinicopathologic characteristics
of gastric cancer in a young patient population. J Gastrointest Surg. 2004 Mar-Apr;8(3):240-4.
94. Rautelin H, Kosunen TU.: Helicobacter pylori infection in Finland. Ann. Med. 2004;36(2):82-8. Review.
95. Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G, Uggeri F.: Biological, histological, and
clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol. 2004 Dec
15;88(4):240-7.
96. Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, de Braud F.:
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in
advanced gastric carcinoma: a phase I-II trial. Ann. Oncol. 2004 May;15(5):759-64.
97. Roukos DH.: Early-stage gastric cancer: a highly treatable disease. Ann. Surg. Oncol. 2004 Feb;11(2):127-9.
98. Saikawa Y, Kubota T, Maeda S, Otani Y, Kumai K, Kitajima M.: Inhibition of DNA methyltransferase by antisense
oligodeoxynucleotide modifies cell characteristics in gastric cancer cell lines. Oncol Rep. 2004 Sep;12(3):527-31.
99. Sakakura C, Takemura M, Hagiwara A, Shimomura K, Miyagawa K, Nakashima S, Yoshikawa T, Takagi T, Kin S,
Nakase Y, Fujiyama J, Hayasizaki Y, Okazaki Y, Yamagishi H.: Overexpression of dopa decarboxylase in peritoneal
dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with
real-time RT-PCR. Br. J. Cancer. 2004 Feb 9;90(3):665-71.
100. Sakamoto J, Morita S, Kodera Y, Rahman M, Nakao A.: Adjuvant chemotherapy for gastric cancer in Japan: global
and Japanese perspectives. Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S25-31. Review.
101. Sawai M, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K.: Growth-inhibitory effects of the ketone body,
monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency.
Anticancer Res. 2004 Jul-Aug;24(4):2213-7.
102. Schoffski P.: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid
tumors. Anticancer Drugs. 2004 Feb;15(2):85-106. Review.
103. Shah MA, Schwartz GK.: Treatment of metastatic esophagus and gastric cancer. Semin Oncol. 2004 Aug;31(4):574-
87. Review.
104. Sherman PM.: Appropriate strategies for testing and treating Helicobacter pylori in children: when and how? Am J
Med. 2004 Sep 6;117 Suppl 5A:30S-35S. Review.
105. Shi Y, Hu W, Yin F, Sun L, Liu C, Lan M, Fan D.: Regulation of drug sensitivity of gastric cancer cells by human
calcyclin-binding protein (CacyBP). Gastric Cancer. 2004;7(3):160-6.
106. Shin YH, Kim TI, Shin MS, Juon HS.: Effect of acupressure on nausea and vomiting during chemotherapy cycle for
Korean postoperative stomach cancer patients. Cancer Nurs. 2004 Jul-Aug;27(4):267-74.
107. Shirin H, Birkenfeld S, Shevah O, Levine A, Epstein J, Boaz M, Niv Y, Avni Y.: Application of Maastricht 2-2000
guidelines for the management of Helicobacter pylori among specialists and primary care physicians in israel: are we
missing the malignant potential of Helicobacter pylori? J Clin Gastroenterol. 2004 Apr;38(4):322-5.
108. Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis Ch, Vardakis N,
Christophilakis Ch, Kotsakis A, Georgoulias V.: Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as firstline
treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann. Oncol. 2004
Aug;15(8):1204-9.
109. Stahl M.: Adjuvant chemoradiotherapy in gastric cancer and carcinoma of the oesophago-gastric junction. Onkologie.
2004 Feb;27(1):33-6.
110. Sulkes A.: Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments. Isr Med Assoc J.
2004 Jul;6(7):415-9. Review.
111. Sullivan T, Ashbury FD, Fallone CA, Naja F, Schabas R, Hebert PC, Hunt R, Jones N.: Helicobacter pylori and the
prevention of gastric cancer. Can J Gastroenterol. 2004 May;18(5):295-302. Review.
112. Sutter AP, Zeitz M, Scherubl H.: Recent results in understanding molecular pathways in the medical treatment of
esophageal and gastric cancer. Onkologie. 2004 Feb;27(1):17-21.
113. Suzuki M, Suzuki H, Masaoka T, Tanaka S, Suzuki K, Ishii H.: Helicobacter pylori eradication treatment modulates
epithelial cell proliferation and tissue content of hepatocyte growth factor in the gastric mucosa. Aliment. Pharm. Ther.
2004 Jul;20 Suppl 1:158-64.
114. Suzuki N, Aoki D, Oie S, Horiuchi M, Hasegawa Y, Ezawa S, Suzuki A, Susumu N, Hosoi F, Kitazato K, Nozawa
S.: A novel retinoid, 4-(3,5-bis (trimethylsilyl) benzamido) benzoic acid (TAC-101), induces apoptosis of human ovarian
carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. Gynecol Oncol. 2004
Sep;94(3):643-9.
115. Tahara M, Ochiai A, Fujimoto J, Boku N, Yasui W, Ohtsu A, Tahara E, Yoshida S.: Expression of thymidylate
synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical
outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep. 2004 Jan;11(1):9-15.
116. Takahashi Y, Kitakata H, Yamashita K, Yasumoto K, Omote K, Minamoto T, Mai M.: Pilot study of low-dose,
divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer. Surg
Today. 2004;34(3):246-50.
117. Takahashi Y, Sakamoto J, Takeuchi T, Mai M, Kubota T, Kitajima M, Tanigawara Y, Komatsu Y, Toge T, Saji S.:
A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric
carcinoma as the first line chemotherapy. Jpn J Clin Oncol. 2004 Jun;34(6):342-5.
118. Takano S, Honda I, Watanabe S, Soda H, Nagata M, Hoshino I, Takenouchi T, Miyazaki M.: PIVKA-II-producing
advanced gastric cancer. Int J Clin Oncol. 2004 Aug;9(4):330-3. Review.
119. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, Toge T, Yahata H, Tanaka S, Chayama K,
Okazaki Y, Hayashizaki Y, Hiyama K, Nishiyama M.: Concise prediction models of anticancer efficacy of 8 drugs
using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26.
120. Tang C, Liu C, Zhou X, Wang C.: Enhanced inhibitive effects of combination of rofecoxib and octreotide on the
growth of human gastric cancer. Int J Cancer. 2004 Nov 10;112(3):470-4.
121. Tominaga K, Higuchi K, Okazaki H, Suto R, Hamaguchi M, Tanigawa T, Sasaki E, Shiba M, Watanabe T,
Fujiwara Y, Oshitani N, Matsumoto T, Arakawa T.: Safety and efficacy of S-1, a novel oral fluorouracil antitumor
drug, for a chronic renal failure patient maintained on hemodialysis. Oncology. 2004;66(5):358-64.
122. Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, Watanabe M, Kumai K, Kitajima M.: Thymidylate
synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining
chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 2004 Jul-Aug;24(4):2455-63.
123. Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA.: S-1-induced, prolonged complete
regression of lung metastasis from gastric cancer refractory to 5′-DFUR: a case report with pharmacokinetic study. Jpn J
Clin Oncol. 2004 May;34(5):282-6.
124. Ushijima T, Sasako M.: Focus on gastric cancer. Cancer Cell. 2004 Feb;5(2):121-5. Review.
125. Uslu A, Karaca C, Nart A, Adagulu H, Aykas A, Gurkan A, Dogan.: Adjuvant chemotherapy in a unique population
of patients with gastric cancer undergoing surgery. Hepatogastroenterology. 2004 Jul-Aug;51(58):1245-8.
126. Vannelli A, Fiore F, Del Conte C, Rivolta U, Corsi C.: Pylethrombosis associated with gastric cancer in Moschcowitz’s
disease: successful management with anticoagulant. Report of a case. Tumori. 2004 Mar-Apr;90(2):259-61.
127. Weber WA, Ott K.: Imaging of esophageal and gastric cancer. Semin Oncol. 2004 Aug;31(4):530-41. Review.
128. Wilson D, Hiller L, Geh I.: ECF in gastric cancer. Clin Oncol (R Coll Radiol). 2004 Aug;16(5):381-2.
129. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY,
Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric
cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004 Jan 14;291(2):187-94.
130. Wood LA, Fields AL.: Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of
medical oncologists. Br. J. Cancer. 2004 May 17;90(10):1885-7.
131. Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR.: Meta-analysis of intraperitoneal chemotherapy for gastric cancer.
World J Gastroenterol. 2004 Sep 15;10(18):2727-30.
132. Yamao T, Ohta K, Ohyama S, Ishihara S, Chin K, Maruyama M, Takahashi T, Nakajima T.: A preliminary study of
preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic
lymph node metastases. Jpn J Clin Oncol. 2004 May;34(5):255-61.
133. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, Saito H, Iwase H, Tsuji Y, Tamura T, Yamamoto S,
Yoshida S.: Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated
gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol. 2004 Jun;34(6):316-22.
134. Yano M, Yasuda T, Fujiwara Y, Takiguchi S, Miyata H, Monden.: Preoperative intraperitoneal chemotherapy for
patients with serosa-infiltrating gastric cancer. J Surg Oncol. 2004 Oct 1;88(1):39-43.
135. Ye M, Pan HM, Wang HY, Lou F, Jin W, Zheng Y, Wu JM.: Catheterization-associated complications of
intraperitoneal chemotherapy in advanced gastric cancer. World J Gastroenterol. 2004 May 1;10(9):1372-4.
136. Yeh KH, Cheng AL.: Recent advances in therapy for gastric cancer. J Formos Med Assoc. 2004 Mar;103(3):171-85.
Review.
137. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T.: Phase I
study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res.
2004 May-Jun;24(3b):1843-51.
138. Yoshimizu N, Otani Y, Saikawa Y, Kubota T, Yoshida M, Furukawa T, Kumai K, Kameyama K, Fujii M, Yano M,
Sato T, Ito A, Kitajima.: Anti-tumour effects of nobiletin, a citrus flavonoid, on gastric cancer include: antiproliferative
effects, induction of apoptosis and cell cycle deregulation. Aliment. Pharm. Ther. 2004 Jul;20 Suppl 1:95-101.
139. Zhang CW, Zou SC, Shi D, Zhao DJ.: Clinical significance of preoperative regional intra-arterial infusion
chemotherapy for advanced gastric cancer. World J Gastroenterol. 2004 Oct 15;10(20):3070-2.
